Evopoint Solutions

Evopoint Solutions company information, Employees & Contact Information

We are a leading consulting firm, recognized for delivering comprehensive solutions and services in technology to foster digital transformation across the North American, The Netherlands and Dominican Republic markets. Our expertise extends to: - Application and Infrastructure Management: Revolutionizing business support with innovative and preventive models. - Cloud Computing and Business Intelligence: Offering sustainable cloud services and enhancing business intelligence with adaptive methodologies. - Enterprise Portals: Creating internal and external portals for collaboration, customer engagement, and brand positioning. - Staff Augmentation: Providing top-tier talent to scale your team efficiently. - Cybersecurity: Safeguarding digital assets with advanced security solutions. - DevOps Services: Enhancing collaboration and automating software delivery across all platforms. - Machine Learning: Leveraging data for predictive analytics and intelligent decision-making. Our approach is grounded in the latest methodologies and strict quality controls, ensuring durable and effective solutions for modern business challenges.
Looking for a particular Evopoint Solutions employee's phone or email?

Evopoint Solutions Questions

News

Astellas Enters Exclusive License Agreement with Evopoint Biosciences for XNW27011, a Novel Clinical-stage Antibody-Drug Conjugate Targeting CLDN18.2 - PR Newswire

Astellas Enters Exclusive License Agreement with Evopoint Biosciences for XNW27011, a Novel Clinical-stage Antibody-Drug Conjugate Targeting CLDN18.2 PR Newswire

Precision redefined: EMUGE’s EvoGrip and EvoPoint integration - Today's Medical Developments

Precision redefined: EMUGE’s EvoGrip and EvoPoint integration Today's Medical Developments

Astellas strikes $1.34B deal with Evopoint for CLDN18.2-directed ADC - FirstWord Pharma

Astellas strikes $1.34B deal with Evopoint for CLDN18.2-directed ADC FirstWord Pharma

Astellas and Evopoint sign ADC licensing deal - Pharmaceutical Technology

Astellas and Evopoint sign ADC licensing deal Pharmaceutical Technology

Astellas Stays Competitive in Hot Gut Cancer Target, Paying $130M to License Evopoint Drug - MedCity News

Astellas Stays Competitive in Hot Gut Cancer Target, Paying $130M to License Evopoint Drug MedCity News

Astellas secures exclusive rights to develop Evopoint’s XNW27011 - World Pharmaceutical Frontiers

Astellas secures exclusive rights to develop Evopoint’s XNW27011 World Pharmaceutical Frontiers

Astellas nabs Evopoint’s CLDN18.2-targeting ADC for $1.34B - BioWorld MedTech

Astellas nabs Evopoint’s CLDN18.2-targeting ADC for $1.34B BioWorld MedTech

Astellas Keeps Chinese Collab Train Chugging With $1.5B+ Bet for Claudin ADC - BioSpace

Astellas Keeps Chinese Collab Train Chugging With $1.5B+ Bet for Claudin ADC BioSpace

Astellas inks ADC deal with Evopoint Biosciences for XNW27011 - The Pharma Letter

Astellas inks ADC deal with Evopoint Biosciences for XNW27011 The Pharma Letter

Astellas adds to claudin clout with $1.3bn+ Evopoint deal - pharmaphorum

Astellas adds to claudin clout with $1.3bn+ Evopoint deal pharmaphorum

Astellas aspires to strike CLDN18.2 gold again with ADC licensing deal worth up to $1.34B - Fierce Biotech

Astellas aspires to strike CLDN18.2 gold again with ADC licensing deal worth up to $1.34B Fierce Biotech

Evopoint doesn't follow Pfizer into prostate cancer | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

Evopoint doesn't follow Pfizer into prostate cancer | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

Eyes on Asia: Regeneron, Astellas, Bristol Myers Squibb - BioXconomy

Eyes on Asia: Regeneron, Astellas, Bristol Myers Squibb BioXconomy

Lepu sees pancreatic cancer promise for tissue factor | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

Lepu sees pancreatic cancer promise for tissue factor | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

#ASCO25 Tracker: BioNTech, OSE Tout Positive Data in Difficult Cancers - BioSpace

#ASCO25 Tracker: BioNTech, OSE Tout Positive Data in Difficult Cancers BioSpace

ASCO 2025 – Astellas's new Claudin18.2 interest | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

ASCO 2025 – Astellas's new Claudin18.2 interest | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

Roundup: Pharma Giants Expand Strategic Pipelines Through Targeted M&A and Partnerships - Pharmaceutical Executive

Roundup: Pharma Giants Expand Strategic Pipelines Through Targeted M&A and Partnerships Pharmaceutical Executive

ESMO 2025 preview – Astellas's third Claudin18.2 shot | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

ESMO 2025 preview – Astellas's third Claudin18.2 shot | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

Tissue factor tempts Adcendo | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

Tissue factor tempts Adcendo | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

After zolbetuximab investors look for a Claudin18.2 encore | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

After zolbetuximab investors look for a Claudin18.2 encore | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

METiS Announces License Agreement with Evopoint Biosciences - Business Wire

METiS Announces License Agreement with Evopoint Biosciences Business Wire

Top Evopoint Solutions Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant